we conclude that IL22 promotes Kras-mutant lung tumorigenesis by driving a protumor inflammatory microenvironment with proliferative, angiogenic, and stemness contextual cues in epithelial/tumor cells.

Up-regulation of interleukin-22 is associated with non-small cell lung carcinoma.

Results show that disease lavage IL-22 concentrations are highest in patients with pneumonia and lung cancer and does not significantly correlate with systemic inflammation.

Data suggest that HGF, IL-20, and IL-22 in the serum and bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) patients before chemotherapy may be a prognostic of cancer progression.

The current data indicated that elevated Notch1 induced higher IL-22 secretion by CD4(+) T cells in lung adenocarcinoma patients, and Notch-AhR-IL-22 axis took part in the pathogenesis of lung adenocarcinoma.